The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 348:252-254 January 16, 2003 Number 3
NextNext

Immunosurveillance against Cancer and Immunotherapy — Synergy or Antagonism?
Thierry Boon, Ph.D., and Nicolas van Baren, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Zhang, L.
-PubMed Citation
Immunologists have long been alert to the possibility that the immune system eliminates many cancers at an early stage and slows down the progress of others.1 In recent years, the concept of immune surveillance against cancer has received support from experiments in mice. An increased incidence of spontaneous or methylcholanthrene-induced tumors was observed in mice lacking interferon-{gamma}, interferon-{gamma} receptors, or perforin and also in mice deficient in recombinase-activating gene 2, which have severe immunodeficiency.2 Processes other than immune rejection of tumor cells may contribute to these results,3 but it is likely that in mice, the immune system can eliminate . . . [Full Text of this Article]


Source Information

From the Ludwig Institute for Cancer Research, Université de Louvain, Brussels, Belgium.


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.